שפּיץ קסנומקס ווינסטראָל בענעפיץ איר דאַרפֿן צו וויסן איידער קויפן ווינסטראָל אָנליין

[1] Balcells G, Matabosch X, Ventura R. Detection of stanozolol O- and N-sulfate metabolites and their evaluation as additional markers in doping control. Drug Test Anal. 2017;9:1001–1010. doi:  10.1002/dta.2107.[2] Ampuero J, García ES, Lorenzo MM, Calle R, Ferrero P, Gómez MR. Stanozolol-induced bland cholestasis. Gastroenterol Hepatol. 2014;37:71–72. doi: 10.1016/j.gastrohep.2013.09.009.[3] Bausserman LL, Saritelli AL, Herbert PN. Effects of short-term stanozolol administration on serum lipoproteins in hepatic lipase deficiency. Metabolism. 1997;46:992–996. doi: 10.1016/S0026-0495(97)90267-5.[4] Hansma P, Diaz FJ, Njiwaji C. Fatal liver cyst rupture due to anabolic steroid use: A case presentation. Am J Forensic Med Pathol. 2016;37:21–22. doi: 10.1097/PAF.0000000000000218.[5] El-Serag HB, Kramer J, Duan Z, Kanwal F. Racial differences in the progression to cirrhosis and hepatocellular carcinoma in HCV-infected veterans. Am J Gastroenterol. 2014;109:1427–1435. doi: 10.1038/ajg.2014.214.[6] Harkin KR, Cowan LA, Andrews GA, Basaraba RJ, Fischer JR, DeBowes LJ, Roush JK, Guglielmino ML, Kirk CA. Hepatotoxicity of stanozolol in cats. J Am Vet Med Assoc. 2000;217:681–684. doi: 10.2460/javma.2000.217.681.[7] Stimac D, Milić S, Dintinjana RD, Kovac D, Ristić S. Androgenic/anabolic steroid-induced toxic hepatitis. J Clin Gastroenterol. 2002;35:350–352. doi: 10.1097/00004836-200210000-00013.[8] Büttner A, Thieme D. Side יפעקס of anabolic androgenic steroids: Pathological findings and structure-activity relationships. Handb Exp Pharmacol. 2010;195:459–484. doi: 10.1007/978-3-540-79088-4_19.[9] Xu Y, Goldkorn A. Telomere and telomerase therapeutics in cancer. Genes (Basel) 2016;7:E22. doi: 10.3390/genes7060022.[10] Zhou X, Zhu H, Lu J. PTEN and hTERT gene expression and the correlation with human hepatocellular carcinoma. Pathol Res Pract. 2015;211:316–319. doi: 10.1016/j.prp.2014.11.016.[11] Wojtyla A, Gladych M, Rubis B. Human telomerase activity regulation. Mol Biol Rep. 2011;38:3339–3349. doi: 10.1007/s11033-010-0439-x.[12] OECD . Guidance document on the recognition, assessment, and use of clinical signs as humane endpoints for experimental animals used in safety evaluation. OECD; Paris: 2000.[13] Zar T, Graeber C, Perazella MA. Recognition, treatment, and prevention of propylene glycol toxicity. Semin Dial. 2007;20:217–219. doi: 10.1111/j.1525-139X.2007.00280.x.[14] Akincilar SC, Unal B, Tergaonkar V. Reactivation of telomerase in cancer. Cell Mol Life Sci. 2016;73:1659–1670. doi: 10.1007/s00018-016-2146-9.[15] Jungermann K, Kietzmann T. Zonation of parenchymal and nonparenchymal metabolism in liver. Annu Rev Nutr. 1996;16:179–203. doi: 10.1146/annurev.nu.16.070196.001143.